focus -WSS

focus

author：explore 2025-09-28 00:53:57 - browse：55955

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： EPA limits use of carcinogenic gas for sterilizing medical devices

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

CDC Director Mandy Cohen on transparency, trust, and health

A new crop of companies is reshaping the health data economy

Dems pitch expanding Medicare power to negotiate drug prices

Why patients can’t get everything they want on drug pricing

Ebola: Gilead Sciences antiviral shows promise as new treatment

explore

focus

focus

Walensky prepares to leave CDC — and Congress — behind

WuXi out of biotech trade group, U.S. and China relations to blame

Trump demands the U.S. pay no more for drugs than other countries … again

EPA limits use of carcinogenic gas for sterilizing medical devices

Peter Hotez and the public health issue of online harassment

'Investigate these claims': UFO transparency at center of House hearing

Guidelines to prevent youth baseball injuries need more muscle

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

In age of alternative facts, a scholarly course on calling out crap

What to watch for from Zogenix and Amicus clinical trials

leisure time

'Investigate these claims': UFO transparency at center of House hearing

President Biden's budget: Here's what you might have missed

Rise in cancer among younger people worries and puzzles doctors

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

In the gardens at Boston Children's Hospital, families find sanctuary

Why patients can’t get everything they want on drug pricing

explore

knowledge

leisure time

Wikipedia